Abstract:Background: Ischemic Stroke (IS) stands as one of the primary cerebrovascular diseases profoundly linked with inflammation. In the context of neuroinflammation, an excessive activation of microglia has been observed. Consequently, regulating microglial activation emerges as a vital target for neuroinflammation treatment. Catalpol (CAT), a natural compound known for its anti-inflammatory properties, holds promise in this regard. However, its potential to modulate neuroinflammatory responses in the brain, especially on microglial cells, requires comprehensive exploration. Methods: In our study, we investigated into the potential anti-inflammatory effects of catalpol using lipopolysaccharide (LPS)-stimulated BV2 microglial cells as an experimental model. The production of nitric oxide (NO) by LPS-activated BV2 cells was quantified using the Griess reaction. Immunofluorescence was employed to measure glial cell activation markers. RT-qPCR was utilized to assess mRNA levels of various inflammatory markers. Western blot analysis examined protein expression in LPS-activated BV2 cells. NF-κB nuclear localization was detected by immunofluorescent staining. Additionally, molecular docking and molecular dynamics simulations (MDs) were conducted to explore the binding affinity of catalpol with key targets. Results: Catalpol effectively suppressed the production of nitric oxide (NO) induced by LPS and reduced the expression of microglial cell activation markers, including Iba-1. Furthermore, we observed that catalpol downregulated the mRNA expression of proinflammatory cytokines such as IL-6, TNF-α, and IL-1β, as well as key molecules involved in the NLRP3 inflammasome and NF-κB pathway, including NLRP3, NF-κB, caspase-1, and ASC. Our mechanistic investigations shed light on how catalpol operates against neuroinflammation. It was evident that catalpol significantly inhibited the phosphorylation of NF-κB and NLRP3 inflammasome activation, both of which serve as upstream regulators of the inflammatory cascade. Molecular docking and MDs showed strong binding interactions between catalpol and key targets such as NF-κB, NLRP3, and IL-1β. Conclusion: Our findings support the idea that catalpol holds the potential to alleviate neuroinflammation, and it is achieved by inhibiting the activation of NLRP3 inflammasome and NF-κB, ultimately leading to the downregulation of pro-inflammatory cytokines. Catalpol emerges as a promising candidate for the treatment of neuroinflammatory conditions.

ST2825, a Small Molecule Inhibitor of MyD88, Suppresses NF-κB Activation and the ROS/NLRP3/Cleaved Caspase-1 Signaling Pathway to Attenuate Lipopolysaccharide-Stimulated Neuroinflammation

Interferon Regulatory Factor 5 Mediates Lipopolysaccharide-Induced Neuroinflammation

A CRTH2 Antagonist, CT-133, Suppresses NF-κB Signalling to Relieve Lipopolysaccharide-Induced Acute Lung Injury.

Effects of myeloid differentiation factor 88 inhibitor ST2825 on biological activities of RAW264.7

Z-ligustilide Attenuates Lipopolysaccharide-Induced Proinflammatory Response Via Inhibiting NF-κB Pathway in Primary Rat Microglia

B355252 Suppresses LPS-Induced Neuroinflammation in the Mouse Brain

Short-term Use of MyD88 Inhibitor TJ-M2010-5 Prevents D-Galactosamine/lipopolysaccharide-induced Acute Liver Injury in Mice.

Histone Deacetylase 2 Inhibitor CAY10683 Alleviates Lipopolysaccharide Induced Neuroinflammation Through Attenuating TLR4/NF-κB Signaling Pathway

Inhibition of Myeloid Differentiation Factor 88(myd88) by ST2825 Provides Neuroprotection after Experimental Traumatic Brain Injury in Mice.

Mechanisms of Anti-Inflammatory Property of Conserved Dopamine Neurotrophic Factor: Inhibition of JNK Signaling in Lipopolysaccharide-Induced Microglia.

Z-Ligustilide Inhibits LPS-induced Neuroimflammation via PPARγ-dependent Suppression of TLR4/NF-κB Signaling Pathway

Dalesconols B Inhibits Lipopolysaccharide Induced Inflammation and Suppresses NF-κB and P38/jnk Activation in Microglial Cells

Pterostilbene Exerts Anti-Neuroinflammatory Effect on Lipopolysaccharide-Activated Microglia Via Inhibition of MAPK Signalling Pathways

The Anti-inflammatory Effects of 4-((5-Bromo-3-chloro-2-hydroxybenzyl) amino)-2-hydroxybenzoic Acid in Lipopolysaccharide-Activated Primary Microglial Cells

N-Salicyloyl Tryptamine Derivatives as Potent Neuroinflammation Inhibitors by Constraining Microglia Activation via a STAT3 Pathway

Inhibition of Autotaxin and Lysophosphatidic Acid Receptor 5 Attenuates Neuroinflammation in LPS-Activated BV-2 Microglia and a Mouse Endotoxemia Model

Catalpol reduced LPS induced BV2 immunoreactivity through NF-κB/NLRP3 pathways: an in Vitro and in silico study

A Novel Quinolyl-Substituted Analogue of Resveratrol Inhibits LPS-Induced Inflammatory Responses in Microglial Cells by Blocking the NF-κB/MAPK Signaling Pathways

2-Cyclohexylamino-5,8-dimethoxy-1,4-naphthoquinone Inhibits LPS-induced BV2 Microglial Activation Through MAPK/NF-kB Signaling Pathways

Inhibition of Monoacylglycerol Lipase by NSD1819 as an Effective Strategy for the Endocannabinoid System Modulation against Neuroinflammation-Related Disorders

Novel TSPO Ligand 2-Cl-MGV-1 Can Counteract Lipopolysaccharide Induced Inflammatory Response in Murine RAW264.7 TMacrophage Cell Line and Lung Models